Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Signal Transduction and Targeted Therapy (3)
Nature Communications (1)
Nature (1)
Nature Immunology (1)
Scientific Reports (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (7)

Subject Check one or more subjects to show results from those subjects only.

Biotechnology
Diseases
Health care
Immunology
Medical research
Microbiology
Pathogenesis
Zoology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–7 of 7 results

Advanced filters: Author: Zhanlong He Clear advanced filters

Lysosomal “TRAP”: a neotype modality for clearance of viruses and variants

Inspired by the idea of mimicking virus entry to host cells and macrophage-mediated virus clearance, the authors developed a lysosomal “TRAP”, which could efficiently capture, internalize, and degrade viruses and variants.

Chengliang Lyu
Zhanlong He
Wei Wei
ResearchOpen Access23 Nov 2024
Nature Communications

Volume: 15, P: 1-21
Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization

An inhalable, single-dose dry powder aerosol SARS-CoV-2 vaccine shows good storage stability, results in sustained antigen delivery to antigen-presenting cells in the lungs and induces a potent antiviral immune response.

Tong Ye
Zhouguang Jiao
Wei Wei
Research13 Dec 2023
Nature

Volume: 624, P: 630-638
An engineered bispecific human monoclonal antibody against SARS-CoV-2

Although COVID-19 vaccines are proving to be generally effective, new therapeutics to neutralize SARS-CoV-2 are required. Here, the authors engineer bispecific antibodies from ACE2-blocking B38 and H4 SARS-CoV-2 neutralizing antibodies and demonstrate their superiority in mice and nonhuman primates.

Zhaohui Li
Shihua Li
Yan Wu
Research28 Feb 2022
Nature Immunology

Volume: 23, P: 423-430
Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern

Tianhong Xie
Shuaiyao Lu
Zhongping Xie
ResearchOpen Access25 Feb 2022
Signal Transduction and Targeted Therapy

Volume: 7, P: 1-9
Rapidly developable therapeutic-grade equine immunoglobulin against the SARS-CoV-2 infection in rhesus macaques

Xiaolei Liu
Yi Liu
Mingyuan Liu
ResearchOpen Access07 Jul 2022
Signal Transduction and Targeted Therapy

Volume: 7, P: 1-3
Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates

Qian He
Qunying Mao
Miao Xu
ResearchOpen Access03 Mar 2022
Signal Transduction and Targeted Therapy

Volume: 7, P: 1-11
Vertical transmission of hepatitis E virus in pregnant rhesus macaques

Wenhai Yu
Xianhui Hao
Fen Huang
ResearchOpen Access15 Oct 2020
Scientific Reports

Volume: 10, P: 1-12